Taysha Gene Therapies Inc (TSHA)
3.09
-0.05
(-1.59%)
USD |
NASDAQ |
May 17, 16:00
3.08
-0.01
(-0.32%)
After-Hours: 20:00
Taysha Gene Therapies Cash from Investing (Quarterly): -0.14M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -0.14M |
| December 31, 2023 | -0.01M |
| September 30, 2023 | -3.49M |
| June 30, 2023 | 0.048M |
| March 31, 2023 | -3.90M |
| December 31, 2022 | -2.37M |
| September 30, 2022 | -3.02M |
| June 30, 2022 | -8.113M |
| March 31, 2022 | -11.43M |
| Date | Value |
|---|---|
| December 31, 2021 | -8.52M |
| September 30, 2021 | -4.002M |
| June 30, 2021 | -8.498M |
| March 31, 2021 | -0.534M |
| December 31, 2020 | -6.051M |
| September 30, 2020 | -0.031M |
| June 30, 2020 | -3.00M |
| March 31, 2020 | 0.00 |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-11.43M
Minimum
Mar 2022
0.048M
Maximum
Jun 2023
-3.709M
Average
-3.02M
Median
Sep 2022
Cash from Investing (Quarterly) Benchmarks
| Aquestive Therapeutics Inc | -0.029M |
| Lifecore Biomedical Inc | -7.50M |
| Relmada Therapeutics Inc | 10.06M |
| ACADIA Pharmaceuticals Inc | -14.04M |
| Cyclacel Pharmaceuticals Inc | 0.00 |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -19.80M |
| Cash from Financing (Quarterly) | -0.022M |
| Free Cash Flow | -76.24M |
| Free Cash Flow Per Share (Quarterly) | -0.0862 |
| Free Cash Flow to Equity (Quarterly) | -19.94M |
| Free Cash Flow Yield | -16.23% |